Argenica Therapeutics Ltd (AGN)

Announcements

Company Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Directors & Management

Name	Title	Since	Bio
Mr Terrence (Terry) Charles Budge	Non-Executive Director	Jan 2021	Mr Terrence (Terry) Charles Budge Non-Executive Director Mr Budge was a Director of Aspen Group Limited from 6 May 2005 to 23 November 2012. He was also Chancellor of Murdoch University from 2006 to 2013 (appointed to Senate 1 June 2004). He is currently a non-executive director and Chairman of the Audit Committee of Westoz Investment Company Ltd (ASX:WIC). He is also the Chairman of the Risk Management Committee of the AGN.
Ms Elizabeth (Liddy) McCall	Non-Executive Director	Dec 2020	Ms Elizabeth (Liddy) McCall Non-Executive Director Ms McCall has co-founded early state venture fund, Yuuwa Capital LP and has over 20 years' experience as a founder, investor and in management of early-stage startups. Her prior experience includes co-founder of iCeutica Inc group, Dimerix Limited (ASX: DXB) and Argus Biomedical Pty Ltd. Previously, Ms McCall was an Associate Director, Macquarie Bank focusing on mergers and acquisitions. Ms McCall is on the Board of various companies including ASX listed AdAlta Limited (ASX:1AD), and unlisted companies, Agworld Pty Ltd, Nexgen Plants Pty Ltd, The Tailor Made Spirits Company Limited and Super Trans Medical Limited. She is also member of the Risk Management Committee of the AGN.
Dr Samantha (Sam) South	Executive Director	Mar 2020	Dr Samantha (Sam) South Executive Director Dr South is currently the Senior Commercialisation Officer (Life Sciences) in the Research Development & Innovation office at UWA and has over 12 years' experience in technology transfer in medtech / biotech sector, at the University of Queensland (UQ), Queensland University of Technology and the University of Western Australia (UWA). Dr South has background in medical research at Weill Medical College at Cornell University (NY), UQ and The Garvan Institute in CNS research. She was also the Preclinical Manager at TetraQ, a preclinical contract organisation, specializing in central nervous system animal models. Dr South was the UWA Director on UWA spin-out companies, MiReven Pty Ltd, Eridan Technologies Pty Ltd and OncoRes Medical Pty Ltd and is currently a Director of Rage Biotech Pty Ltd. Dr South is also the WA Ausbiotech Committee Chair and part of the Ausmedtech National Advisory Group and SBE Life Sciences Council.
Mr Geoffrey (Geoff) Richard Pocock	Non-Executive Chairman,Non-Executive Director	Nov 2019	Mr Geoffrey (Geoff) Richard Pocock Non-Executive Chairman,Non-Executive Director Mr Pocock has over 20 years' experience across the commercialisation process. Mr Pocock's experience has covered technical roles, executive management as well as corporate finance and strategy roles with a number of technology commercialisation ventures. Mr Pocock is the Principal of Polaris Consulting, a specialist boutique commercialisation strategy and executive services advisory business based in Western Australia, which also provides administrative services to businesses. He is also currently an Executive Director of Osteopore Ltd (ASX:OSX) and NonExecutive Director of EMVision Medical Devices Ltd (ASX:EMV) and former Managing Director/Co-Founder of Hazer Group (ASX: HZR). He is also member of the Risk Management Committee of the AGN.
Ms Emma Waldon	Chief Financial Officer,Company Secretary	N/A
Dr Liz Dallimore	Chief Executive Officer	N/A
Liz Dallimore	Chief Executive Officer	N/A

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Terrence (Terry) Budge	21/01/2021	N/A	455,000	500,000	N/A
Elizabeth (Liddy) McCall	16/12/2020	N/A	125,000	500,000	N/A
Samantha (Sam) South	24/03/2020	N/A	2,000,000	1,000,000	N/A
Geoffrey (Geoff) Pocock	20/11/2019	N/A	4,377,000	500,000	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Oofy Prosser Pty Ltd (Drones Family A/C)	4,377,000	5.98%
University Of Western Australia	3,953,000	5.40%
Perron Institute For Neurological And Translational Science Ltd	3,550,000	4.85%
Shane Michael Colley (Fiery King Investment A/C)	2,000,000	2.73%
Shane Hoehock Wee (Wee Family A/C)	1,794,250	2.45%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) (i)	1,750,000	2.39%
Arredo Pty Ltd	1,550,000	2.12%
Litis Super Pty Ltd (Jde Litis Super Fund A/C)	1,500,000	2.05%
Helen Margaret Sewell	1,472,500	2.01%
Xcel Capital Pty Ltd	1,462,500	2.00%
Bruno Philip Meloni (Bruno Meloni Family A/C)	1,277,000	1.75%
Ga Skylight Berhad	1,250,000	1.71%
Mr Neville William Knuckey & Mrs Jacqueline Joy Knuckey	1,072,000	1.47%
Busso Holdings Pty Ltd (Bew)	1,025,000	1.40%
Asenna Wealth Solutions Pty Ltd	900,000	1.23%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) (ii)	872,500	1.19%
Pentek Holdings Pty Ltd (The J Litis Investment No.2 A/C)	785,000	1.07%
Hugh James Pilgrim (The HJP Family A/C)	734,500	1.00%
Morsec Nominees Pty Ltd (Accumulation Account)	690,000	0.94%
Kdjama Co Pty Ltd (Blacker Services A/C)	655,750	0.90%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

AGN Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.